



Pharmaceuticals Limited

Registered & Corporate Office :

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,
Opp. SBI Executive Enclave, Banjara Hills,
Hyderabad - 500 034, Telangana, INDIA.
Tel : +91-40-2525 9999, Fax : +91-40-2525 9889
CIN : L24239TG1987PLC008066
Email: info@smspharma.com, www.smspharma.com

Date: 25th May, 2023

To
The Manager,
Corporate Filings Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001.

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Security Code: 532815

Symbol: SMSPHARMA

Dear Sir/Madam,

**Sub: Newspaper cuttings of published financial results for Fourth Quarter and
Financial Year ended March 31, 2023**

Pursuant to Regulation 47 read with Regulation 33, we enclose copies of the newspaper Advertisements published in The Financial Express (English), and in Andhra Prabha (Telugu), on 25th May, 2023 regarding the Audited Standalone & Consolidated Financial Results for the fourth quarter and financial year ended March 31, 2023.

This information is also being made available on the website of the Company www.smspharma.com.

Please take the above intimation on your records.

Thanking you
Yours faithfully

For SMS Pharmaceuticals Limited

**Thirumalesh Tumma
Company Secretary**

भारतीय कंटेनर निगम लिमिटेड
CONTAINER CORPORATION OF INDIA LTD.
 (एनएसई एंड एनएसई) (A Navratna Undertaking of Govt. of India)
 NSIC New MDP Building, 2nd Floor, Okhla Ind. Estate (Opp. NSIC Okhla Metro Station), New Delhi-110023

Open Tender Notice (e-Tendering mode only)

Online E-bids are invited for Design, Manufacture, Supply and Commissioning of 100 nos of 40 feet 3 Axle flat bed SEMI TRAILERS at CMLK Khatwas terminal of CONCOR through Two packet e-tendering mode.

Bid Reference: Tender No. CON/AREA-1/TECH/40/SEMI TRAILER-100/2023
Tendered Quantity: 100 Nos.
Estimated Cost: Rs. 14.71, 32,000/-
Estimated Money Deposit (EMD):* Rs. 10 Lakhs through online payment gateway to CONCOR.
Cost of Document† Rs. 1,000/- through online payment gateway to CONCOR.
Tender processing fee (Non-refundable)† Rs. 4720/- (Inclusive of Taxes) through online payment

Period of Tender Sale (online): From 25.05.2023 at 16:00 Hrs to 15.06.2023 at upto 17:00 Hrs.
Date and Time of Submission of Bid: 16.06.2023 at 17:00 Hrs.
Date and Time of opening of Bid: 19.06.2023 at 11:00 Hrs.

***Through e-Payment**
 For eligibility criteria and other details please log into www.concorindia.com or e-procure.gov.in or www.tenderwizard.com/CCIL. Bidders are requested to visit the website regularly. CONCOR reserves the right to reject any or all the tenders without assigning any reasons therefor. For complete details login www.tenderwizard.com/CCIL.

Group General Manager/TI/Area-1

भारतीय कंटेनर निगम लिमिटेड
Container Corporation of India Ltd.
 (एनएसई एंड एनएसई) (A Govt. of India Undertaking)

Tender No. CON/A-CIVIL/AMC/T-1/2023 (NOTICE INVITING E-TENDER)

CONCOR invites E-Tender in Single Packet System of tendering for the following work:-

Name of Work: Repair and Maintenance of Civil Work Of Corporate Office at C-3, Mathura Road, NSIC-MDBP Building (2nd & 3rd Floor), CONCOR Officers Flats at Defence Colony, Jungpura, Khelgaon, San Martin Marg, Chanakyapuri, Technical Office at US Complex (Room No. 6,7,12 & 19), 27 Tilak Bridge Railway Colony New Delhi & Operational Office at Gurgaon.

Estimated Cost: Rs. 276.08 Lakhs inclusive all taxes

Completion Period: 24 (Twenty Four) Months

Earnest Money Deposit: Rs. 2,88,100/- (through e-payment)

Cost of Tender Document: NIL

Tender Processing Fee (Non-refundable): Rs. 4,720/- (inclusive all taxes & duties through e-payment)

Date of sale of Tender (online): 25.05.2023 (11:00 hrs) to 14.06.2023 (upto 17:00 hrs)

Date & Time of submission of Tender: 15.06.2023 upto 17:00 hrs

Date & Time of Opening of Tender: 16.06.2023 at 11:30 hrs

For financial eligibility criteria, experience with respect to similar nature of work, etc, please refer to detailed tender notice available on website www.concorindia.com, but the complete tender document can be downloaded from website www.tenderwizard.com/CCIL only. Further, Corrigendum / Addendum to this Tender, if any, will be published on website www.concorindia.com, www.tenderwizard.com/CCIL, and Central Procurement Portal (CPP) only. Newspaper press advertisement shall not be issued for the same.

Executive Director (P&S)/A-II Phone No.: 011-41222500

IMPORTANT

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever. Registered letters are not accepted in response to box number advertisement.*

Biocon

Registered Office: Biocon Limited, 20th KM Holar Road, Electronic City Phase 2, Bangalore - 560 100
 www.biocon.com
 CIN: L24236KA1978PLC003417

EXTRACT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2023
 (Rs. in Million, except per equity share data)

Particulars	3 months ended	Year ended	Year ended
	31.12.2023	31.03.2023	31.03.2022
	Audited	Audited	Audited
I Revenue from operations	37,739	1,11,742	81,840
II Profit before exceptional items and tax	4,996	11,885	10,942
III Profit before tax	4,966	8,971	9,831
IV Profit attributable to shareholders of the Company	3,132	4,627	6,484
V Total comprehensive income attributable to shareholders of the Company	2,503	5,765	7,451
VI Paid-up equity share capital [Face value of Rs. 5 each]	6,003	6,003	6,003
VII Reserve [Excluding Revaluation Reserve] as shown in the audited balance sheet		1,72,657	78,313
VIII Earnings per share (of Rs. 5 each)	(not annualised)	(annualised)	(annualised)
(a) Basic	2.62	3.88	5.44
(b) Diluted	2.62	3.87	5.42

1. Key standalone financial information

Particulars	3 months ended	Year ended	Year ended
	31.12.2023	31.03.2023	31.03.2022
	Audited	Audited	Audited
I Revenue from operations	5,067	19,929	17,382
II Profit before tax	17,961	29,712	1,397
III Net Profit for the period	18,108	28,484	861

2. The audited standalone and consolidated financial results for the quarter and year ended March 31, 2023 in respect of Biocon Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on May 23, 2023. The reports of the statutory auditors are unqualified.

3. These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

4. The above is an extract of the detailed format of audited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the audited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.biocon.com.

SMS PHARMACEUTICALS LIMITED
 CIN : L24239TG1987PLC008066

Registered office: Plot.No. 72 H.No. 8-2-334/3&4, Road No. 5 Opp. SBI Executive Enclave, Banjara Hills, Hyderabad, Telangana 500034 IN
 Phone.No: 040-35359999/25259999, website: www.smspharma.com; email complianceofficer@smspharma.com

Extract of audited Financial Results for the Quarter and year Ended 31st March, 2023
 (₹ in Lakhs)

Sl. No.	Particulars	Standalone				Consolidated			
		Quarter ended		Year ended		Quarter ended		Year ended	
		31.03.2023	31.03.2022	31.03.2023	31.03.2022	31.03.2023	31.03.2022	31.03.2023	31.03.2022
1	Total Income from Operations (net)	14,942.55	6,091.90	52,205.14	51,987.43	14,942.55	6,091.90	52,205.14	51,987.43
2	Profit from Ordinary Activities before Tax	1,064.27	(1,617.32)	554.96	6,865.47	1,063.40	(1,632.88)	534.91	6,849.91
3	Profit from Ordinary Activities after Tax (after Extraordinary Items)	807.46	905.98	408.46	6,803.65	621.83	617.42	(705.93)	6,221.99
4	Total Comprehensive Income for the quarter (comprising profit/Loss) for the quarter (after tax) and other comprehensive items	783.39	924.76	387.93	6,807.58	598.76	635.05	(722.38)	6,230.00
5	Equity Share Capital (Face value of share: Re.1/- each)	846.52	846.52	846.52	846.52	846.52	846.52	846.52	846.52
6	Reserves (excluding Revaluation Reserve as per Balance Sheet) Re. 1/- each			48,663.47	48,529.50			45,206.00	46,182.34
7	Earnings per share (before extraordinary items - (Not annualized)								
	Basic/Diluted (in Rs)	0.95	1.07	0.48	8.04	0.73	0.73	(0.83)	7.35

Notes:
 1. The above Standalone and consolidated Financial Results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their meetings held on 24th May, 2023.
 2. These results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed Under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
 3. The above is an extract of detailed format of quarterly / annual financial results filed with the stock exchanges under regulation 33 of the SEBI (LODR) Regulations, 2015. The full format of quarterly / annual financial results are available on the website of the Stock Exchanges of BSE: www.bseindia.com (ID 532815) or NSE: www.nseindia.com (Symbol SMSPHARMA) and companies website (www.smspharma.com).

By and on behalf of Board of Directors
SMS Pharmaceuticals Limited
 Sd/-
Ramesh Babu Potluri (DIN: 00166381)
 Chairman and Managing Director

Place: Hyderabad
 Date: 24-05-2023

JORABAT SHILLONG EXPRESSWAY LIMITED

Registered Office : The IL&FS Financial Center, Plot C-22, G Block, Bandra Kurla Complex, Bandra (East), Mumbai- 400051, India
 Tel : 022-26533333 Fax : 022-26523979 Website : <https://www.itnindia.com/JSEL-SPV.aspx>
 CIN:- U45203MH2010PLC204456

Extract of Audited Financial Results for the Year ended March 31, 2023
 (Rs. in Lakhs)

Particulars	Quarter Ended			Year Ended	
	March 31, 2023	December 31, 2022	March 31, 2022	March 31, 2023	March 31, 2022
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
1 Total Income from Operations	3,797	3,169	3,376	12,420	10,921
2 Net Profit / (Loss) for the period (before tax, Exceptional and/or Extraordinary items)	2,871	2,808	(132)	9,008	(132)
3 Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	2,871	2,808	(132)	9,008	(132)
4 Net Profit / (Loss) for the year after tax (after Exceptional and/or Extraordinary items)	2,871	2,808	(132)	9,008	(132)
5 Total Comprehensive Income for the period (Comprising Profit / (Loss) for the year (after tax) and Other Comprehensive Income (after tax)	2,871	2,808	(132)	9,008	(132)
6 Paid-up equity share capital (face value - ₹ 10 per share)	8,400	8,400	8,400	8,400	8,400
7 Reserves (excluding revaluation Reserve)	(13,839)	(16,710)	(22,847)	(13,839)	(22,847)
8 Securities Premium Amount	-	-	-	-	-
9 Net worth	(5,439)	(8,310)	(14,447)	(5,439)	(14,447)
10 Paid-up Debt Capital	133,169	133,169	133,169	133,169	133,169
11 Outstanding Redeemable Preference Shares	-	-	-	-	-
12 Debt/Equity Ratio (number of times)	(24.48)	(16.02)	(9.22)	(24.48)	(9.22)
13 Earnings per share (of ₹ 10/- each) : (* Not annualised)					
(a) Basic	3.42*	3.34*	3.18*	10.72	(0.16)
(b) Diluted	3.42*	3.34*	3.18*	10.72	(0.16)
14 Capital Redemption Reserve	-	-	-	-	-
15 Debenture Redemption Reserve	8,162	8,162	8,162	8,162	8,162
16 Debt Service Coverage Ratio (DSCR) (number of times)	-	-	-	-	-
17 Interest Service Coverage Ratio (ISCR) (number of times)	-	-	-	-	-

Notes:
 1. The above is an extract of the detailed format of quarterly and yearly results filed with Stock Exchange under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015. The full format of the quarter and year ended financials results are available on the websites of the National Stock Exchange (NSE) - www.nseindia.com and the Company's - www.itnindia.com/JSEL-SPV.aspx
 2. For the items referred in regulation 52 (4) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, the pertinent disclosures have been made to the Stock Exchange (NSE) and can be accessed on the (www.nseindia.com) and on the Company's website - www.itnindia.com/JSEL-SPV.aspx
 3. The above results are in compliance with Indian Accounting Standards ('Ind AS') notified by the Ministry of Corporate Affairs, read with SEBI Circular No. CIR/IMD/DF/69/2016 dated August 10, 2016
 4. The above financial results of the Company were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 24, 2023 and has been reviewed by the Statutory Auditor of the Company

For and on behalf of the Board
 Rajnish Saxena
 Non-Executive Director
 DIN : 05188337

Date: May 24, 2023

INDIA GLYCOLS LIMITED

Regd. Office: A-1, Industrial Area, Bazpur Road, Kashipur - 244 713, Distt. Udham Singh Nagar (Uttarakhand)
 Phones: +91 5947 269000/269500, Fax: +91 5947 275315/269535
 Email: compliance.officer@india glycols.com, Website: www.india glycols.com • CIN: L24111UR1983PLC009097

Audited Financial Results for the Quarter & Year ended March 31, 2023
 (₹ In Crore, except as stated)

Sl. No.	Particulars	STANDALONE				CONSOLIDATED				
		Quarter Ended		Year Ended		Quarter Ended		Year Ended		
		31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2023	31.12.2022	31.03.2022	31.03.2023	
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	
1	Total income from operations	1,619.74	1,532.48	1,498.34	6,668.45	6,622.86	1,620.12	1,531.41	1,498.97	6,665.53
2	Profit before Interest, depreciation and Tax (EBDITA)	100.93	80.55	85.77	325.11	278.90	100.48	76.14	84.42	319.42
3	Net profit/(Loss) for the period (before Tax, Exceptional and/or extraordinary items)	45.90	34.15	49.85	140.27	140.75	44.33	27.48	45.38	125.50
4	Net profit/(Loss) for the period before tax (after Exceptional and/or extraordinary items)	45.90	16.58	10.60	122.70	341.38	45.64	53.26	31.82	165.00
5	Net profit/(Loss) for the period after tax (after Exceptional and/or extraordinary items)	40.10	13.35	19.02	98.74	275.12	39.84	50.03	67.08	141.04
6	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and other Comprehensive Income (after tax))	40.41	13.36	18.93	99.08	285.32	40.58	50.10	66.90	141.44
7	Equity Share Capital	30.96	30.96	30.96	30.96	30.96	30.96	30.96	30.96	30.96
8	Other Equity as shown in the Audited Balance Sheet				1,556.65	1,480.80				1,870.46
9	Earnings Per Share (of ₹ 10/- each) (Not Annualised) - Basic & Diluted (in ₹)	12.95	4.31	6.14	31.89	88.86	12.87	16.16	21.67	45.55

Notes:
 1. The above is an extract of the detailed format of Quarterly/Yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Yearly Financial Results are available on the Stock Exchanges Websites (www.bseindia.com and www.nseindia.com) and on the Company's website (www.india glycols.com).
 2. The Board of directors have recommended a dividend @ ₹ 7.50/- per share of face value of ₹ 10/- each subject to the approval of the members of the Company at its ensuing Annual General Meeting.

for INDIA GLYCOLS LIMITED
 Sd/-
U.S. BHARTIA
 Chairman and Managing Director
 DIN: 00063091

Place : Noida
 Date : 24th May, 2023

Svantra Microfin Private Limited

Regd. Office: Sunshine Tower, Level 20, Senapati Bapat Marg, Elphinstone Road, Mumbai - 400013
 Website: www.svantramicrofin.com Email: secretarial@svantra.adityabirla.com CIN: U74120MH2012PTC227069
 [Regulation 52 (B), read with Regulation 52 (4), of the SEBI (LODR) Regulations, 2015]

Extract of Audited Financial Results for the quarter and financial year ended 31 March 2023
 (Rs. in Lakhs except per share data)

Sr. No.	Particulars	Quarter ended	Quarter ended	Quarter ended	Year ended	Year ended
		31/03/2023	31/12/2022	31/03/2022	31/03/2023	31/03/2022
		(Audited)	(Reviewed)	(Audited)	(Audited)	(Audited)
1	Total Income from Operations	37,154	38,410	25,036	136,697	81,974
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	7,966	3,585	4,565	17,224	6,309
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	7,966	3,585	4,565	17,224	6,309
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	6,057	2,678	3,514	12,977	4,727
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	6,058	2,680	3,517	13,000	4,685
6	Paid up Equity Share Capital	25,205	25,205	25,205	25,205	25,205
7	Reserves (Excluding Revaluation Reserve)	24,261	18,183	11,213	24,261	11,213
8	Securities Premium Account	4	4	4	4	4
9	Net worth (including Compulsory Convertible Non-Cumulative Preference Shares)	114,966	103,888	86,918	114,966	86,918
10	Paid up Debt Capital / Outstanding Debt	626,058	562,672	480,434	626,058	480,434
11	Outstanding Redeemable Preference Shares	-	-	-	-	-
12	Debt Equity Ratio	5.45	5.42	5.53	5.45	5.53
13	Earnings Per Share (of Rs. 10/- each)					
	1. Basic:	0.80	0.38	0.64	1.78	0.88
	2. Diluted:	0.80	0.38	0.64	1.78	0.88
14	Capital Redemption Reserve	NA	NA	NA	NA	NA
15	Debenture Redemption Reserve	NA	NA	NA	NA	NA
16	Debt Service Coverage Ratio	NA	NA	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA	NA	NA

Notes: a) The above is an extract of the detailed format of audited Financial Results filed with BSE Limited under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the audited Financial Results is available on the website of BSE (www.bseindia.com) and on the Company's website (www.svantramicrofin.com).
 b) For the other line items referred in regulation 52(4) of the LODR Regulation, pertinent disclosures have been made to the BSE and can be accessed on the website of BSE (www.bseindia.com) and on the Company's website (<https://svantramicrofin.com>).

By order of the Board
 For Svantra Microfin Private Limited
 Sd/-
Ms. Ananyashree Birla (Director)
 DIN: 06625036

Place : Mumbai
 Date : 23.05.2023

ICRA Limited

Corporate Identity Number (CIN): L74999DL1991PLC042749
 Registered Office: B-710, Statesman House, 14B, Barakhamba Road, New Delhi-110001
 Telephone No.: +91-11-23357940, Website: www.icra.in, Email ID: investors@icraindia.com

EXTRACT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2023
 (₹ in lakh)

S. No.	Particulars	Quarter ended	Year ended	Quarter ended	Year ended
		March 31, 2023	March 31, 2023	March 31, 2022	March 31, 2022
		(Audited)	(Audited)	(Audited)	(Audited)
1	Total income from operations	6,187.80	22,253.79	5,235.65	19,473.14
2	Net profit / (loss) for the period (before tax, exceptional and/or extraordinary items)	3,104.79	11,713.23	2,643.98	9,334.87
3	Net profit / (loss) for the period before tax (after exceptional and/or extraordinary items)	3,104.7			

